Selecting Appropriate Treatments for Patients With Unresectable Kidney Cancer
Elizabeth Wulff-Burchfield, MD, advises physicians on how to make appropriate treatment decisions for patients with unresectable kidney cancer.
Elizabeth Wulff-Burchfield, MD, assistant professor, Divisions of Medical Oncology and Palliative Medicine and medical director of Palliative and Geriatric Oncology Services, The University of Kansas Health System, advises physicians on how to make appropriate treatment decisions for patients with unresectable kidney cancer.
Treatment decisions should primarily depend on several patient characteristics, such as their functional status, goals for treatment, and tolerance for medical burden, Wulff-Burchfield says. Should the patient’s goal be to pursue more aggressive care and systemic therapy in order to both achieve good responses and improve symptom burden, she says she would prioritize treatment based on overall responses rates.
For patients who are more medically frail, or have comorbidities putting them at a higher risk for a rapid decline in function status or overall well-being, it is reasonable to consider a single-agent tyrosine inhibitor, according to Wulff-Burchfield. If a patient can tolerate more aggressive care, it would be appropriate to use a tyrosine kinase inhibitor in combination with an immune checkpoint inhibitor.
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
